During Thursday’s Current trade, Shares of Qlik Technologies Inc (NASDAQ:QLIK), lost -2.17% to $36.91.
Raised data volumes and numerous data sources are changing the dynamic of how federal agencies are able to process, analyze and make critical decisions, according to a new study conducted by Market Connections on behalf of Qlik® (QLIK), a leader in visual analytics. According to the study, 97 percent of agencies stated they must compile data from more than one data source; 65 percent of agencies report not having a data analytics solution in place to consolidate data from multiple sources into one interface.
The study, which surveyed 200 respondents – 34 percent Defense and 66 percent Civilian – confirms that quick, easy to digest data is vital to improved decision-making. According to the results, 68 percent of respondents believe one of the greatest benefits of data analytics is the ability to make better, quicker fact-based decisions.
“Centralizing data for public agencies raises concerns about security and data governance,” said Lisa Dezzutti, President and CEO of Market Connections. “Having the ability to quickly access, analyze and disseminate information gives agencies the ability to make better decisions that will improve overall efficiency and service.”
Qlik Technologies Inc. provides user-driven business intelligence solutions that enable customers to make business decisions. The company develops, commercializes, and implements software products and related services.
Shares of UBS Group AG (USA) (NYSE:UBS), declined -1.20% to $19.73, during its current trading session.
The UBS Global Asset Administration US Pension Fund Fitness Tracker saw the funding ratio of the typical corporate US pension plan fall by about five percentage points to 82% in the third quarter of 2015.
“In the third quarter, we saw the funding ratios of pension plans decrease as both investment returns in addition to liability returns were unfavorable. Over the course of the full year many plans have seen a substantial aggregate negative net effect on the overall funding ratios. Because of that, some plans have started to re-risk due to upward adjustments of predictable return targets. Other plans have not yet taken action, but we do expect more shifts in allocations given the reduced levels of funding ratios. We continue to advise our clients on appropriate strategy and timing of implementation of new allocation targets,” said Frank van Etten, head of Client Solutions at UBS Global Asset Administration.
Negative investment returns of -3.1%, together with positive liability returns of 2.5%, led to nearly a 5 percentage point drop in funding ratios over the third quarter. Widening credit spreads failed to offset lower Treasury yields this quarter. These estimates are based on the average corporate plan’s stated asset allocation weightings from the UBS Global Asset Administration Pension 500 Database and publicly accessible benchmark information.
UBS Group AG, together with its auxiliaries, provides wealth administration, retail and corporate, asset administration, and investment banking products and services worldwide. The company’s Wealth Administration division provides financial services to wealthy private clients.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI), during its Thursday’s current trading session decreased -0.13% to $7.78.
Infinity Pharmaceuticals, Inc. (INFI) will provide an update on the clinical development program and commercial overview for duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and talk about the company’s immuno-oncology development candidate, IPI-549, at its Research and Development (R&D) Day this morning from 8:00am (ET) to 11:45am (ET) in New York City. During recently’s presentations, Infinity will review its anticipated timelines for the development and commercialization of duvelisib. The company recently declared that the 120th patient has been enrolled in DYNAMO™, a Phase 2 study in patients with refractory indolent non-Hodgkin lymphoma (iNHL), and topline data from this study are anticipated in the third quarter of 2016. Infinity will also review the IPI-549 data presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference and talk about the planned Phase 1 study for IPI-549 in solid tumors.
“We are entering into an exciting time for Infinity,” stated Julian Adams, the company’s president, research and development. “During our R&D Day, we will provide a thorough review of our duvelisib program, counting preclinical and clinical data that support our registration focused trials in iNHL and CLL, DYNAMO and DUO, respectively, and outline our clinical development strategy to further differentiate duvelisib. We are extremely happy to have some of the top experts in leukemia, lymphoma and immuno-oncology to provide the physician’s perspective based on their knowledge and experience, and we also look forward to sharing the innovative science that led to IPI-549.”
Recently Infinity also declared that William (Bill) Bertrand has been designated to the role of executive vice president, general counsel, effective October 19, 2015, reporting to Adelene Perkins, chair, president and chief executive officer.
Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate comprises IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
